Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi's Diabetes Sales Force Increase Not Due To Threat From Exubera Or Levemir, Exec Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi attributes its increased detailing focus on the diabetes market to changing prescribing trends, not increased competition.

You may also be interested in...

Novo Nordisk Emphasizes Levemir “Predictability”

Planned second quarter launch would be nearly one year after FDA approval.

Pfizer Breathes Easy: FDA Approves Exubera

Pfizer's Exubera is the first inhaled insulin to clear FDA; labeling recommends lung function testing.

Pfizer Banking On Exubera Approval

The firm acquires Sanofi-Aventis’ rights to the inhaled insulin product through a change-in-control clause.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts